Hard-charging GSK research chief Hal Barron touts improved anti-BCMA data, aiming for fast applications
GlaxoSmithKline R&D chief Hal Barron touted a fresh set of updated data on their anti-BCMA antibody drug conjugate GSK2857916 on Thursday, pointing to a solid 60% response rate from their DREAMM-1 study on multiple myeloma as he burnished the pharma giant’s improved late-stage prospects in oncology.
Image: Hal Barron. GSK
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,600+ biopharma pros reading Endpoints daily — and it's free.